To take the right action, you need the right insights. It's time for change.
Let's measure heart disease, not surrogates.
Cleerly helps HCPs go beyond traditional measures of heart disease by analyzing, characterizing, and quantifying types of plaque, so they can more accurately determine a patient's risk of heart attack and develop a personalized treatment plan to improve heart health - no matter where they are on the heart disease continuum.
Gain new insights. Save more lives.
Cleerly's easy-to-read reports provide healthcare professionals with a more precise understanding of patient risk, from vessel-to-vessel detail and comprehensive plaque assessment to stenosis scoring. Cleerly gives HCPs the insights they need to translate clinical data into a customized treatment plan for each patient, helping them save more lives.
Phenotyping: it's the characterization of disease that matters most.
Cleerly's AI-enabled, digital care pathway characterizes and quantifies atherosclerotic plaque in the arteries, letting you know not only how much is there but what type and amount of plaque is present. Plaque type has been shown to be the strongest discriminant of future heart attack risk, and perhaps the greatest indicator of your patient's likelihood of an impending cardiac event.
Staging atherosclerosis assists providers with patient evaluation as well as individualizing treatment. Stabilizing high-risk plaques has been achieved with lifestyle changes and medical therapy through the transformation of non-calcified fatty plaques to calcified stable plaques.
Transformation of non-calcified high-risk plaques to calcified low-risk plaques has been shown to be associated with reduced rates of major adverse cardiovascular events.